Core Viewpoint - Symbotic, Inc. reported its fourth-quarter earnings, meeting EPS estimates and exceeding revenue expectations, leading to a rise in stock price [1][2]. Financial Performance - The company reported quarterly losses of $0.03 per share, aligning with analyst estimates [2]. - Quarterly revenue reached $618.46 million, surpassing the Street estimate of $604 million and increasing from $576.77 million in the same period last year, reflecting a year-over-year growth [2]. Management Commentary - CEO Rick Cohen highlighted the company's commitment to strong top-line growth, operational system expansion, and margin improvement for fiscal year 2025, emphasizing the addition of Medline as a new customer in the healthcare sector [3]. Future Outlook - For the first quarter of fiscal 2026, Symbotic anticipates revenue between $610 million and $630 million, with adjusted EBITDA projected at $49 million to $53 million [4]. - Following the earnings report, Symbotic's stock price increased by 6.76%, reaching $59.21 in extended trading [4].

Core Insights - Walmart Inc. reported a strong quarterly performance, leading to a 6% increase in stock price, indicating positive investor sentiment [1] Financial Performance - The company demonstrated effective management and operational success during the quarter, contributing to the favorable stock price reaction [1]

Core Insights - TJX Companies reported better-than-expected third-quarter financial results, with adjusted earnings per share at $1.28, surpassing the analyst consensus of $1.23, and revenue reaching $15.1 billion, exceeding expectations of $14.84 billion, marking a 7% increase year-over-year [1] Financial Performance - The company achieved a pretax profit margin of 12.7%, exceeding its forecast and expanding by 0.4 percentage points from the previous year [2] - Gross margin improved to 32.6%, up 1.0 percentage point year-over-year, driven by higher merchandise margins and improved expense leverage [2] Sales Performance - Comparable-store sales rose by 5%, significantly above the company's internal projections, with TJX Canada leading at 8%, followed by Marmaxx in the U.S. at 6%, HomeGoods at 5%, and TJX International at 3% [2] Shareholder Returns - The company returned $1.1 billion to shareholders during the quarter, which included $594 million for repurchasing 4.2 million shares and $472 million in dividend payments [3] Future Outlook - TJX maintained its full-year comparable sales growth target of 4% and raised its pretax profit margin forecast to 11.6% [3] - For the fourth quarter, the retailer projected comparable sales growth of 2% to 3% and EPS of $1.33 to $1.36, slightly below the analyst expectation of $1.37 [3]

Key Points It notched a pair of beats in its fiscal third quarter of 2026. This was mitigated by a slight miss on fourth-quarter earnings guidance. 10 stocks we like better than TJX Companies › TJX Companies (NYSE: TJX) published its latest set of quarterly earnings on Wednesday, which were sufficient to push the retailer's stock higher. Although the company beat the consensus analyst estimates for both sales and profitability, its guidance left something to be desired. Across-the-board growth In ...

Core Insights - NetEase, Inc. is set to release its quarterly earnings on November 20, 2025, with analysts expecting an EPS of $2.08 and revenue of approximately $4.1 billion, which will provide insights into the company's financial health and market performance [1][6] Financial Metrics - The company has a price-to-earnings (P/E) ratio of 18.45, indicating how the market values its earnings, and a price-to-sales (P/S) ratio of 5.71, reflecting the market value relative to its revenue [2][6] - The enterprise value to sales ratio is 5.32, and the enterprise value to operating cash flow ratio is 12.53, providing context on the company's total valuation compared to its sales and cash flow from operations [3] - An earnings yield of 5.42% suggests a return on investment based on earnings, which can be attractive to investors [3] Financial Health - NetEase maintains a conservative capital structure with a debt-to-equity ratio of 0.075, indicating limited reliance on debt and contributing to financial stability [4][6] - The current ratio of 3.23 highlights the company's strong liquidity, ensuring it can effectively cover short-term liabilities [4][6] Upcoming Events - The earnings release will be accompanied by a teleconference call and webcast at 7:00 a.m. Eastern Time, allowing management to discuss results and address questions, with a replay available until November 27 [5]

Company Performance - Barrick's revenue totaled US$4.15 billion, an increase from US$3.37 billion year-over-year [1] - Barrick's adjusted earnings per share rose to 58 cents, compared to 30 cents per share a year ago [1] - MEG Energy reported net earnings of $159 million, down from $167 million in the same period last year [5][7] - Loblaw's profit attributable to common shareholders was $794 million, up from $777 million a year ago [9][13] - Manulife's net income attributed to shareholders was $1.8 billion, slightly down from $1.84 billion year-over-year [15] Production and Pricing - Barrick's gold production decreased to 829,000 ounces from 943,000 ounces a year ago, while the realized gold price increased to US$3,457 per ounce from US$2,494 per ounce [2] - Copper production for Barrick rose to 55,000 tonnes from 48,000 tonnes, with a realized copper price of US$4.39 per pound, up from US$4.27 per pound [2] - MEG Energy's production reached a record of 108,166 barrels per day, compared to 103,298 barrels per day in the prior-year quarter [6] Dividends and Corporate Changes - Barrick increased its quarterly base dividend to 12.5 cents per share from 10 cents, with an additional performance dividend of five cents per share, totaling 17.5 cents per share [3] - Barrick appointed Mark Hill as interim president and CEO following the departure of Mark Bristow, and is seeking a permanent replacement [3] Market Trends - Loblaw's food retail same-store sales increased by 2%, while drug retail same-store sales rose by 4%, with pharmacy and health-care same-store sales growth of 5.9% [11] - Manulife's core earnings in Asia and Canada reached record levels, with US$550 million in Asia and US$428 million in Canada [16]

Core Insights - Flutter Entertainment Inc. reported mixed third-quarter earnings, with earnings per share of $1.64 surpassing the Street estimate of 86 cents, while quarterly revenue of $3.79 billion fell short of the analyst estimate of $3.9 billion [1][2] Financial Performance - The company experienced a solid third quarter, with continued momentum in both US and International businesses, maintaining its position as the number one operator in the U.S. [2] - The adjusted EBITDA for Q3 was reported at $51 million, reflecting a 12% year-over-year decline [4] Revenue Outlook - Flutter lowered its fiscal 2025 revenue outlook to $16.69 billion from the previous estimate of $17.05 billion [2] Market Reaction - Following the earnings report, Flutter Entertainment's stock was down 2.1% in extended trading, priced at $229.50 [3] Business Segment Performance - Sportsbook revenue declined by 5% year-over-year due to temporary impacts from sports results and high levels of competition during the NFL season start [4] - The company noted a 10% year-over-year handle growth in Q4 to date, attributed to increased investment in FanDuel and a strong start to the NBA season [4]

Core Insights - Adaptive Biotechnologies reported a revenue of $93.97 million for the quarter ended September 2025, marking a year-over-year increase of 102.4% and exceeding the Zacks Consensus Estimate of $68.02 million by 38.15% [1] - The company posted an EPS of -$0.15, an improvement from -$0.22 a year ago, with a surprise of 6.25% compared to the consensus estimate of -$0.16 [1] Revenue Performance - ClonoSEQ test volume reached 27,111, surpassing the average estimate of 26,482 based on three analysts [4] - Total Immune Medicine revenues were reported at $37.19 million, significantly higher than the average estimate of $11.95 million, reflecting a year-over-year change of 314.8% [4] - Revenues from MRD-Regulatory milestone stood at $6.5 million, exceeding the average estimate of $2.08 million [4] - Total MRD revenues were $56.79 million, compared to the average estimate of $48.74 million, representing a year-over-year increase of 51.6% [4] - MRD-Service revenue was reported at $50.29 million, slightly above the average estimate of $46.66 million [4] - Immune Medicine revenue from collaboration reached $33.74 million, significantly higher than the two-analyst average estimate of $10.36 million, with a year-over-year change of 860.8% [4] - Immune Medicine revenue from service was $3.44 million, below the estimated $4.37 million, reflecting a year-over-year decline of 36.9% [4] Stock Performance - Shares of Adaptive Biotechnologies have returned +17.9% over the past month, outperforming the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - NMI Holdings Inc. (NMIH) reported third-quarter 2025 operating net income per share of $1.21, matching the Zacks Consensus Estimate, with a year-over-year increase of 5.2% [1][7] - The quarterly results were driven by higher premiums earned, improved net investment income, and consistent growth in the high-quality insured portfolio, although this was offset by lower persistency [1] Operational Update - Total operating revenues for NMI Holdings reached $179 million, reflecting a 7.8% year-over-year increase, driven by a 5.5% rise in net premiums earned and a 19.1% increase in net investment income, surpassing the Zacks Consensus Estimate by 2.3% [2] - Primary insurance in force grew by 5.2% to $218.4 billion, while annual persistency decreased to 83.9%, down 160 basis points year over year [2] - New insurance written amounted to $13 billion, marking a 6.4% increase year over year [2] Underwriting and Operating Expenses - Underwriting and operating expenses totaled $29.2 million, showing a slight decrease of 0.01% year over year [3] - Insurance claims and claim expenses surged by 80.5% year over year to $18.6 million, resulting in a loss ratio of 12.3, which deteriorated by 510 basis points [3] - The adjusted expense ratio improved by 100 basis points to 19.3, while the adjusted combined ratio worsened by 400 basis points to 31.5 [3] Financial Update - Book value per share increased by 17.8% year over year to $32.62 as of September 30, 2025 [4] - Cash and cash equivalents stood at $130.4 million, more than doubling from the end of 2024, while the debt balance rose by 0.3% to $416.5 million [4] - The annualized adjusted return on equity contracted by 200 basis points to 15.5% year over year [4] PMIERs and Risk-Based Assets - Total PMIERs available assets were reported at $3.4 billion, with net risk-based required assets totaling $2 billion at the end of the third quarter of 2025 [5]

Core Insights - Somnigroup International (SGI) is expected to report quarterly earnings of $0.85 per share, reflecting a 3.7% increase year over year, with revenues projected at $2.07 billion, a significant 59% year-over-year growth [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 4.2% in the last 30 days, indicating analysts' reassessment of their initial projections [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Net Sales- Direct' at $1.32 billion, representing a remarkable increase of 316.1% from the previous year [5]. - 'Net Sales- Wholesale' is projected to be $716.71 million, indicating a decrease of 27% year over year [5]. - 'Net Sales- International' is expected to reach $308.79 million, reflecting an 8.5% increase from the prior year [5]. Regional Sales Estimates - 'Net Sales- North America' is anticipated to be $732.72 million, showing a decline of 27.8% from the previous year [6]. - 'Net Sales- North America- Wholesale' is forecasted at $605.19 million, indicating a year-over-year decrease of 31.1% [6]. - 'Net Sales- International- Direct' is estimated at $196.52 million, reflecting an 8.4% increase from the prior year [6]. Additional Sales Insights - 'Net Sales- International- Wholesale' is projected to be $111.52 million, suggesting a year-over-year increase of 7.9% [7]. - 'Net Sales- North America- Direct' is expected to reach $107.39 million, indicating a decline of 21.6% year over year [7]. Market Performance - SGI shares have shown a return of -4.4% over the past month, contrasting with the Zacks S&P 500 composite's +1% change [7]. - With a Zacks Rank 2 (Buy), SGI is anticipated to outperform the overall market in the near future [7].